Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.87 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.87 |
| ▸ | KDR | P35968 | 3/20 | 0.87 |
| ▸ | GAK | O14976 | 1/20 | 0.87 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.87 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.87 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.87 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.87 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.87 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.87 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.87 |
| ▸ | TGFB2 | P61812 | 1/20 | 0.87 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.87 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.87 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.87 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.87 |
| ▸ | THRB | P10828 | 6/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414159 | 0.95 | TGFBR1 (0.87) | TGFBR1MAPK14KDRGAKRIPK2 | |
| Galunisertib SCHEMBL12922153 | 0.93 | TGFBR1 (1.00) | TGFBR1MAPK14KDRGAKRIPK2 | |
| Galunisertib SCHEMBL29362145 | 0.93 | TGFBR1 (1.00) | TGFBR1MAPK14KDRGAKRIPK2 | |
| Galunisertib SCHEMBL29438525 | 0.92 | TGFBR1 (0.98) | TGFBR1MAPK14KDRGAKRIPK2 | |
| SCHEMBL373341 | 0.91 | TGFBR1 (1.00) | TGFBR1MAPK14KDRGAKRIPK2 | |
| SCHEMBL16695915 | 0.91 | TGFBR1 (0.81) | TGFBR1MAPK14KDRGAKRIPK2 | |
| SCHEMBL29773207 | 0.91 | TGFBR1 (0.95) | TGFBR1MAPK14KDRGAKRIPK2 | |
| SCHEMBL21702385 | 0.90 | TGFBR1 (0.84) | TGFBR1MAPK14KDRGAKRIPK2 | |
| SCHEMBL18347825 | 0.89 | TGFBR1 (0.78) | TGFBR1MAPK14KDRGAKRIPK2 | |
| SCHEMBL23852042 | 0.88 | TGFBR1 (0.80) | TGFBR1MAPK14KDRGAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117026-A1 | COMBINATION THERAPY USING ENANTIOPURE, OXY-SUBSTITUTED, DEUTERIUM-ENRICHED 5-(BENZYL)-5-DEUTERO-THIAZOLIDINE-2,4-DIONES FOR TREATMENT OF MEDICAL DISORDERS | DEUTERX, LLC | 2018-05-03 | — | — | US | disclosed |
| US-20160375142-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2016-12-29 | — | — | US | disclosed |
| US-20140127228-A1 | INHIBITION OF TGFBETA SIGNALING TO IMPROVE MUSCLE FUNCTION IN CANCER | Indiana University School of Medicine (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128349-A1 | ADMINISTERING INHIBITORS OF TGFBETA SIGNALING IN COMBINATION WITH BENZOTHIAZEPINE DERIVATIVES TO IMPROVE MUSCLE FUNCTION IN CANCER PATIENTS | Indiana University School of Medicine (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128349-A1 | ADMINISTERING INHIBITORS OF TGFBETA SIGNALING IN COMBINATION WITH BENZOTHIAZEPINE DERIVATIVES TO IMPROVE MUSCLE FUNCTION IN CANCER PATIENTS | Indiana University School of Medicine (US) | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140127228-A1 | INHIBITION OF TGFBETA SIGNALING TO IMPROVE MUSCLE FUNCTION IN CANCER | MUSK, TGFBR1, TGFBR2 | TGFBR1 2/4885MAPK14 1509/4885KDR 1477/4885 |
| US-20160375142-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | TGFBR1 4466/4885MAPK14 2658/4885KDR 1715/4885 |
| US-20140128349-A1 | ADMINISTERING INHIBITORS OF TGFBETA SIGNALING IN COMBINATION WITH BENZOTHIAZEPINE DERIVATIVES TO IMPROVE MUSCLE FUNCTION IN CANCER PATIENTS | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885MAPK14 1802/4885KDR 3111/4885 |
| US-20180117026-A1 | COMBINATION THERAPY USING ENANTIOPURE, OXY-SUBSTITUTED, DEUTERIUM-ENRICHED 5-(BENZYL)-5-DEUTERO-THIAZOLIDINE-2,4-DIONES FOR TREATMENT OF MEDICAL DISORDERS | PPARD, HNF4A, GLP1R | TGFBR1 808/4885MAPK14 4254/4885KDR 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.